- Home
- Apac Stem Cell Therapy Market
APAC Stem Cell Therapy Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-464 | No of pages: 153 | Format:
The Asia-Pacific stem cell therapy market is projected to register a substantial CAGR of 10.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (South Korea, Japan, and India) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific stem cell therapy market are:
Rise in investment in research and development
Rise in prevalence of chronic diseases
Market Players:
Some of the major players operating in the Asia-Pacific stem cell therapy market are:
JCR Pharmaceuticals Co., Ltd
MEDIPOST
Takeda Pharmaceutical Company Limited
CORESTEM, Inc.
PHARMICELL Co., Ltd.
STEMPEUTICS RESEARCH PVT LTD
ANTEROGEN.CO., LTD
U.S. Stem Cell, Inc.
Mesoblast Ltd
Orthofic Medical Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE ASIA PACIFIC STEM CELL THERAPY MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22
2 ASIA PACIFIC STEM CELL THERAPY MARKET: SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.6 MULTIVARIATE MODELLING 31
2.7 PRODUCT SEGMENT LIFELINE CURVE 31
2.8 DBMR MARKET POSITION GRID 32
2.9 VENDOR SHARE ANALYSIS 34
2.10 MARKET END USER COVERAGE GRID 35
2.11 SECONDARY SOURCES 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 41
4.1 PESTEL 42
4.2 PORTER'S FIVE FORCES MODEL 43
5 EPIDEMIOLOGY 44
6 PIPELINE ANALYSIS FOR THE ASIA PACIFIC STEM CELL THERAPY MARKET 45
7 ASIA PACIFIC STEM CELL THERAPY MARKET: REGULATIONS 46
8 MARKET OVERVIEW 49
8.1 DRIVERS 51
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 51
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 52
8.1.3 GROWING BIOTECHNOLOGY SECTOR 53
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 54
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 54
8.2 RESTRAINTS 55
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 55
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 55
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 56
8.2.4 AVAILABILITY OF ALTERNATIVES 56
8.3 OPPORTUNITIES 57
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 57
8.3.2 RISE IN HEALTHCARE EXPENDITURE 57
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 58
8.4 CHALLENGES 58
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 58
8.4.2 STRINGENT REGULATIONS 59
9 ASIA PACIFIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE 61
9.1 OVERVIEW 62
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 65
9.3 PLACENTAL/UMBILICAL STEM CELL 65
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 66
9.5 OTHERS 67
10 ASIA PACIFIC STEM CELL THERAPY MARKET, BY TYPE 69
10.1 OVERVIEW 70
10.2 ALLOGENEIC STEM CELL THERAPY 73
10.2.1 MUSCULOSKELETAL DISORDERS 74
10.2.2 WOUNDS AND INJURIES 74
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 74
10.2.4 SURGERIES 74
10.2.5 GASTROINTESTINAL DISEASES 74
10.2.6 OTHER APPLICATION 74
10.3 AUTOLOGOUS STEM CELL THERAPY 74
10.3.1 CARDIOVASCULAR DISEASES 76
10.3.2 GASTROINTESTINAL DISEASES 76
10.3.3 OTHER APPLICATION 76
11 ASIA PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION 77
11.1 OVERVIEW 78
11.2 MUSCULOSKELETAL DISORDERS 80
11.3 WOUNDS AND INJURIES 81
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 82
11.5 SURGERIES 83
11.6 GASTROINTESTINAL DISEASES 84
11.7 CARDIOVASCULAR DISEASES 84
11.8 OTHER APPLICATION 85
12 ASIA PACIFIC STEM CELL THERAPY MARKET, BY END USER 87
12.1 OVERVIEW 88
12.2 HOSPITAL AND SURGICAL CENTERS 91
12.3 THERAPEUTIC COMPANIES 91
12.4 SERVICES COMPANIES 92
12.5 OTHERS 93
13 ASIA PACIFIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 94
13.1 OVERVIEW 95
13.2 DIRECT TENDER 99
13.3 THIRD PARTY DISTRIBUTORS 99
14 ASIA PACIFIC STEM CELL THERAPY MARKET, BY REGION 101
14.1 ASIA-PACIFIC 102
14.1.1 SOUTH KOREA 108
14.1.2 JAPAN 110
14.1.3 INDIA 112
15 ASIA PACIFIC STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 114
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 114
16 SWOT ANALYSIS 115
17 COMPANY PROFILE 116
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 116
17.1.1 COMPANY SNAPSHOT 116
17.1.2 REVENUE ANALYSIS 116
17.1.3 COMPANY SHARE ANALYSIS 117
17.1.4 PRODUCT PORTFOLIO 117
17.1.5 RECENT DEVELOPMENT 117
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 118
17.2.1 COMPANY SNAPSHOT 118
17.2.2 REVENUE ANALYSIS 118
17.2.3 COMPANY SHARE ANALYSIS 119
17.2.4 PRODUCT PORTFOLIO 119
17.2.5 RECENT DEVELOPMENTS 119
17.3 ORTHOFIX MEDICAL INC. (2021) 120
17.3.1 COMPANY SNAPSHOT 120
17.3.2 REVENUE ANALYSIS 120
17.3.3 COMPANY SHARE ANALYSIS 121
17.3.4 PRODUCT PORTFOLIO 121
17.3.5 RECENT DEVELOPMENTS 121
17.4 MEDIPOST (2021) 123
17.4.1 COMPANY SNAPSHOT 123
17.4.2 REVENUE ANALYSIS 123
17.4.3 COMPANY SHARE ANALYSIS 124
17.4.4 PRODUCT PORTFOLIO 124
17.4.5 RECENT DEVELOPMENTS 124
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 126
17.5.1 COMPANY SNAPSHOT 126
17.5.2 REVENUE ANALYSIS 126
17.5.3 COMPANY SHARE ANALYSIS 127
17.5.4 PRODUCT PORTFOLIO 127
17.5.5 RECENT DEVELOPMENT 127
17.6 CORESTEM, INC. (2021) 128
17.6.1 COMPANY SNAPSHOT 128
17.6.2 REVENUE ANALYSIS 128
17.6.3 PRODUCT PORTFOLIO 129
17.6.4 RECENT DEVELOPMENT 129
17.7 PHARMICELL CO., LTD. (2021) 130
17.7.1 COMPANY SNAPSHOT 130
17.7.2 PRODUCT PORTFOLIO 130
17.7.3 RECENT DEVELOPMENTS 130
17.8 ANTEROGEN.CO., LTD (2021) 131
17.8.1 COMPANY SNAPSHOT 131
17.8.2 PRODUCT PORTFOLIO 131
17.8.3 RECENT DEVELOPMENTS 131
17.9 ATHERSYS, INC.(2021) 132
17.9.1 COMPANY SNAPSHOT 132
17.9.2 REVENUE ANALYSIS 132
17.9.3 PRODUCT PORTFOLIO 133
17.9.4 RECENT DEVELOPMENTS 133
17.10 BRAINSTORM CELL LIMITED (2021) 134
17.10.1 COMPANY SNAPSHOT 134
17.10.2 PRODUCT PORTFOLIO 134
17.10.3 RECENT DEVELOPMENTS 134
17.11 BIORESTORATIVE THERAPIES, INC. (2021) 136
17.11.1 COMPANY SNAPSHOT 136
17.11.2 REVENUE ANALYSIS 136
17.11.3 PRODUCT PORTFOLIO 137
17.11.4 RECENT DEVELOPMENTS 137
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 138
17.12.1 COMPANY SNAPSHOT 138
17.12.2 PRODUCT PORTFOLIO 138
17.12.3 RECENT DEVELOPMENTS 138
17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 140
17.13.1 COMPANY SNAPSHOT 140
17.13.2 REVENUE ANALYSIS 140
17.13.3 PRODUCT PORTFOLIO 141
17.13.4 RECENT DEVELOPMENT 141
17.14 MESOBLAST LTD (2021) 142
17.14.1 COMPANY SNAPSHOT 142
17.14.2 REVENUE ANALYSIS 142
17.14.3 PRODUCT PORTFOLIO 143
17.14.4 RECENT DEVELOPMENTS 143
17.15 PLURISTEM INC.(2021) 144
17.15.1 COMPANY SNAPSHOT 144
17.15.2 REVENUE ANALYSIS 144
17.15.3 PRODUCT PORTFOLIO 145
17.15.4 RECENT DEVELOPMENT 145
17.16 STEMPEUTICS RESEARCH PVT LTD 146
17.16.1 COMPANY SNAPSHOT 146
17.16.2 PRODUCT PORTFOLIO 146
17.16.3 RECENT DEVELOPMENTS 146
17.17 U.S. STEM CELL, INC. (2021) 148
17.17.1 COMPANY SNAPSHOT 148
17.17.2 REVENUE ANALYSIS 148
17.17.3 PRODUCT PORTFOLIO 149
17.17.4 RECENT DEVELOPMENT 149
18 QUESTIONNAIRE 150
19 RELATED REPORTS 153
Segmentation
Short Description
Asia-Pacific Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (South Korea, Japan, and India) Industry Trends and Forecast to 2029
Market Definition:
Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.
Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or their derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.
Market Segmentation:
The Asia-Pacific stem cell therapy market is categorized into product type, type, applications, end user, and distribution channel.
On the basis of product type, the Asia-Pacific stem cell therapy market is segmented into placental or umbilical stem cell, bone marrow derived mesenchymal cells, adipose tissue derived mesenchymal stem cells, and others
On the basis of type, the Asia-Pacific stem cell therapy market is segmented into allogenic stem cell therapy and autologous stem cell therapy
On the basis of application, the Asia-Pacific stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, and others
On the basis of end user, the Asia-Pacific stem cell therapy market is segmented into hospitals and surgical centers, therapeutic companies, services companies, and others
On the basis of distribution channel, the Asia-Pacific stem cell therapy market is segmented into direct tenders and third party distributor
Market Players
Some of the major players operating in the Asia-Pacific stem cell therapy market are:
JCR Pharmaceuticals Co., Ltd
MEDIPOST
Takeda Pharmaceutical Company Limited
CORESTEM, Inc.
PHARMICELL Co., Ltd.
STEMPEUTICS RESEARCH PVT LTD
ANTEROGEN.CO., LTD
U.S. Stem Cell, Inc.
Mesoblast Ltd
Orthofic Medical Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.